Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic
The coronavirus (COVID-19) pandemic, which began in 2020, has affected all spheres of life, including clinical trial processes. Health authorities around the world issued recommendations aimed at minimising the risks of virus spreading and ensuring the safety of study participants. One of the types...
Main Authors: | D. P. Romodanovsky, A. L. Khokhlov, D. V. Goryachev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
OOO “Vashe Tsifrovoe Izdatelstvo”
2021-03-01
|
Series: | Ведомости Научного центра экспертизы средств медицинского применения |
Subjects: | |
Online Access: | https://www.vedomostincesmp.ru/jour/article/view/358 |
Similar Items
-
Regulatory requirements of the European Medicines Agency for evaluation of bioequivalence of modified-release medicinal products
by: D. P. Romodanovsky, et al.
Published: (2019-03-01) -
Expert Approaches to the Assessment of Losartan Drugs Bioequivalence
by: D. P. Romodanovsky, et al.
Published: (2020-02-01) -
PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS
by: N. E. Uvarova, et al.
Published: (2018-12-01) -
Evaluation of Bioequivalence of Generic Imatinib Products and Generic Tacrolimus Products Based on Indirect Comparison of the Results of Their Bioequivalence Studies
by: D. V. Goryachev, et al.
Published: (2019-09-01) -
Highly variable medicines - specific aspects of bioequivalence studies
by: D. P. Romodanovsky, et al.
Published: (2018-02-01)